BCL11A enhancer editing is currently the most actionable strategy for HBB c.92+1G>A beta-thalassemia

For HBB c.92+1G>A, a canonical splice-donor beta-thalassemia variant, ex vivo gene editing that reactivates fetal hemoglobin is currently more clinically actionable than direct repair of the splice site. The rationale is strong because the therapeutic objective is to restore effective erythropoiesis despite a severe HBB loss-of-function allele, and that has already been shown to be feasible in transfusion-dependent beta-thalassemia with exagamglogene autotemcel.

ClinVar classifies HBB c.92+1G>A as Pathogenic, consistent with a severe splicing defect in beta-globin production. In the phase 3 CLIMB THAL-111 study, exagamglogene autotemcel produced durable transfusion benefit in transfusion-dependent beta-thalassemia by editing autologous hematopoietic stem cells to increase HbF rather than repairing the causal HBB allele directly (PMID:38657265). A 2026 therapeutic review likewise places HbF-reactivating gene therapy among the leading clinical options in beta-thalassemia and highlights the translational maturity of this editing route relative to locus-specific correction strategies (PMID:41919270). For a splice-donor variant such as c.92+1G>A, this mutation-agnostic mechanism is particularly attractive because it bypasses the need to restore exact splicing fidelity at the endogenous HBB locus.

This post is arguing for a genotype-relevant but not allele-corrective strategy. It does not show that HBB c.92+1G>A itself has been directly repaired in a patient-specific preclinical model. Conditioning toxicity, manufacturing complexity, and access constraints remain major practical limitations of ex vivo edited autologous therapy. The cited clinical evidence is at the disease level for transfusion-dependent beta-thalassemia rather than for this exact splice-site allele, so the inference to c.92+1G>A is mechanistic and clinical rather than variant-specific experimental proof.